Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab')2 antivenoms and other drugs
- PMID: 17689580
- DOI: 10.1016/j.toxicon.2007.05.011
Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab')2 antivenoms and other drugs
Abstract
Fast disappearance of F(ab')2 antivenoms from the plasma compartment [Sevcik et al., 2004. Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues. Toxicon 44, 731-734; Vazquez et al., 2005. Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers. Toxicon 46, 797-805] suggests a quick time course to reach its final distribution volume. An equation was developed to describe how the volume occupied by a drug in the body grows with time. As discussed in the paper this equation is free of some shortcomings of an equation developed for the same purpose by Niazi [1976. Volume of distribution as a function of time. J. Pharm. Sci. 65, 452-454]. Fluorescence microscopy showed that the rapid initial decay in plasmatic F(ab')2 concentration may be related to uptake of F(ab')2 by vascular endothelium which, in combination with accumulation in the vascular wall connective tissue, may produce an intermediate plateau in F(ab')2 V(sl)(t), which reached its final value after 10 h. The V(sl)(t) equation predicts that the plasma concentration half-time of decay has little use to estimate how a drug distributes through the body to exert its action, and predicts that, in some instances, intermediate plateaus in the time course of V(sl)(t) exist. Data from the literature showed that the kinetic considerations for V(sl)(t) also apply to clevidipine, digoxin, digitoxin, lidocaine and thiopentone.
Similar articles
-
Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues.Toxicon. 2004 Dec 1;44(7):731-41. doi: 10.1016/j.toxicon.2004.07.032. Toxicon. 2004. PMID: 15500849
-
Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers.Toxicon. 2005 Dec 1;46(7):797-805. doi: 10.1016/j.toxicon.2005.08.010. Epub 2005 Sep 28. Toxicon. 2005. PMID: 16197974 Clinical Trial.
-
Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers.Int Immunopharmacol. 2010 Nov;10(11):1318-24. doi: 10.1016/j.intimp.2010.08.018. Epub 2010 Sep 17. Int Immunopharmacol. 2010. PMID: 20849955 Clinical Trial.
-
Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.Clin Pharmacokinet. 2003;42(8):721-41. doi: 10.2165/00003088-200342080-00002. Clin Pharmacokinet. 2003. PMID: 12846594 Review.
-
Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies.Ann Emerg Med. 2001 Feb;37(2):189-95. doi: 10.1067/mem.2001.113135. Ann Emerg Med. 2001. PMID: 11174238 Review.
Cited by
-
Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa.J Venom Anim Toxins Incl Trop Dis. 2013 Mar 28;19(1):6. doi: 10.1186/1678-9199-19-6. J Venom Anim Toxins Incl Trop Dis. 2013. PMID: 23849079 Free PMC article.
-
Snakebite: When the Human Touch Becomes a Bad Touch.Toxins (Basel). 2018 Apr 21;10(4):170. doi: 10.3390/toxins10040170. Toxins (Basel). 2018. PMID: 29690533 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials